RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
December 26, 2023 12:45 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX AND MEDSAN CONTRACT TO ADVANCE STUDY INTENDED TO PERSONALIZE MEDICAL EVALUATIONS FOR PATIENTS RECEIVING TREATMENT FOR WET MACULAR DEGENERATION
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
December 21, 2023 05:50 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS ANATOLY DRITSCHILO, M.D. TO THE COMPANY’S MEDICAL ADVISORY BOARD
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 13, 2023 07:30 ET
|
Ocugen
MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
November 16, 2023 14:09 ET
|
The Rosen Law Firm PA
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
Ophthalmology PACS (Integrated, Standalone) Market Analysis Report 2023: A Global $248 Million Market by 2030 - Increased Prevalence of Various Eye Diseases Fueling Demand
November 14, 2023 03:28 ET
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Ophthalmology PACS Market Size, Share & Trends Analysis Report By Type (Integrated, Standalone), By Mode Of Action (Cloud-based, On-premise), By...
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
November 08, 2023 05:45 ET
|
RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC and AVANIA CRO CONTRACT to GUIDE the DEVELOPMENT of TWO DRUG THERAPIES and the RETINALCAM™ IMAGE VISUALIZATION DEVICE
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
October 30, 2023 14:51 ET
|
RetinalGeniX Technologies, Inc.
Proposed patient selection process is intended to reduce the cost and improve the safety and efficacy of patient candidate selection for ocular injections
Global Retinal Implant Market Anticipates Rapid Growth, Expected to Reach $112.2 Million by 2030
October 30, 2023 11:18 ET
|
Research and Markets
Dublin, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The "Retinal Implants Market Size, Share & Trends Analysis Report By Device Type (Retina Implant Alpha AMS, Implantable Miniature Telescope, Argus II),...
Global Retinal Vein Occlusion Treatment Market Poised for Remarkable Growth, Expected to Reach $4.18 Billion by 2030
October 30, 2023 11:13 ET
|
Research and Markets
Dublin, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The "Retinal Vein Occlusion Treatment Market Size, Share & Trends Analysis Report By End-user (Retail Pharmacy, Hospital & Clinics), By Disease Type...
Digital Marketing Trends in Age-Related Macular Degeneration, 2023 Research Report Featuring Bayer, Genentech, Novartis, Coherus Biosciences, Bausch & Lomb, Apellis Pharmaceuticals, & Outlook
October 04, 2023 04:47 ET
|
Research and Markets
Dublin, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The "Digital Marketing Trends in Age-Related Macular Degeneration" report has been added to ResearchAndMarkets.com's offering.In an increasingly...